FGFR3 and cancer: FGFR3-TACC3 fusions have been observed in lung (Capelletti et al., 2014; Wang et al., 2014), cervical (Carneiro et al., 2015), bladder (Nassar et al., 2018), and nasopharyngeal (Yuan et al., 2014) cancers and usually lead to increased cell proliferation, in vitro transforming abilities, and activation of MAPK and ERK signaling (Nelson et al., 2016).